Beste apotheek van Nederland

Aizenberg Dov, Gur Shay, Zemishlany Zvi et al. Mianserin, a 5­
HT-sub(2a/2c ) and alpha -sub-2 antagonist, in the treatment of
sexual dysfunction induced by serotonin reuptake inhibitors.
Clin Neuropharmacol 1997;20(3):210-214.
Aizenberg Dov, Weizman Abraham, Barak Yoram et al.
Sildenafil for selective serotonin reuptake inhibitor-induced
erectile dysfunction in elderly male depressed patients.
[References]. J Sex Marital Ther 2003;29(4):297-303.
al-Juburi A Z, O'Donnell P D. Follow up outcome of
intracavernous papaverine. J Ark Med Soc 1990;86(10):383­
385.
Alivizatos G, Skolarikos A, Laguna P. Recent data upon
impotence, incontinence and quality of life issues concerning
radical prostatectomy. [Review] [74 refs]. Arch Esp Urol
2003;56(3):321-330.
Allan C A, McLachlan R I. Age-related changes in testosterone
and the role of replacement therapy in older men. Clin
Endocrinol (Oxf) 2004;60(6):653-670.
Althof S E, Cappelleri J C, Shpilsky A et al. Treatment
responsiveness of the Self-Esteem And Relationship
questionnaire in erectile dysfunction. Urology 2003;61(5):888­
892.
Althof S E, O' Leary M P, Cappelleri J C et al. Self-esteem,
confidence, and relationships in men treated with sildenafil
citrate for erectile dysfunction: results of two double-blind,
placebo-controlled trials. J Gen Intern Med 2006;21(10):1069­
1074.
Altwein J E, Keuler F U. Oral treatment of erectile dysfunction
with apomorphine SL. [Review] [34 refs]. Urol Int
2001;67(4):257-263.
Anderson D C, Seifert C F. Topical nitrate treatment of
impotence. [Review] [17 refs]. Ann Pharmacother
1993;27(10):1203-1205.
Anderson R A, Bancroft J, Wu F C. The effects of exogenous
testosterone on sexuality and mood of normal men. Journal of
Clinical Endocrinology & Metabolism 1992;75(6):1503-1507.
Andersson K-E. Pharmacology of penile erection. Pharmacol
Rev 2001;53(3):417-450.
Anonymous. Sildenafil and erectile dysfunction: new
preparation. Helpful. Prescrire.Int 1998;7(38):163-165.
Anonymous. Sublingual apomorphine: new preparation. In
erectile disorders: a narrow therapeutic margin. Prescrire.Int
2002;11(59):76-79.
Anonymous. Vardenafil (levitra) for erectile dysfunction.
Medical Letter on Drugs & Therapeutics 2003;45(1166):77-78.
Anonymous. Viagra: a blueprint for safety and reliability. Johns
Hopkins Medical Letter, Health After 50 2002;14(10):4-5.
Anonymous. Vasoactive intestinal
peptide/phentolamine. Invicorp, vasopotin. Drugs in R
& D 1999;2(6):436-438.
Anonymous. Treatment for impotence gains FDA
approval. Am J Health Syst Pharm 1995;52(19):2078­
2079.
Anonymous. L-arginine. Altern Med Rev
2005;10(2):139-147.
Anonymous. Use of sildenafil for ED classes II and
III. S Afr Med J 2005;95(1):38
Anonymous. Patient preference of ED drugs studied.
British Journal of Diabetes & Vascular Disease
2003;3(6):444
Anonymous. New drug for erectile dysfunction. Can
Pharm J 2002;268(7200):756
Anonymous. Vardenafil improves erectile function in
men with diabetes. Can Pharm J 2001;267(7155):
Anonymous. Alprostadil for erectile impotence. Drug
& Therapeutics Bulletin 1995;33(8):61-62.
Anonymous. What to do if Viagra won't do. Harvard
Mens Health Watch 2005;9(10):4-8.
Anonymous. Diagnostic and therapeutic technology
assessment. Vasoactive intracavernous
pharmacotherapy for impotence: intracavernous
injection of prostaglandin E1. JAMA
1991;265(24):3321-3323.
Anonymous. Diagnostic and therapeutic technology
assessment. Vasoactive intracavernous
pharmacotherapy for impotence: papaverine and
phentolamine. JAMA 1990;264(6):752-754.
Aranda P, Ruilope L M, Calvo C et al. Erectile
dysfunction in essential arterial hypertension and
effects of sildenafil: results of a Spanish national
study. Am J Hypertens 2004;17(2):139-145.
Ardicoglu A, Kocakoc E, Tuygun U O et al.
Effectiveness of vardenafil versus papaverine in penile
Doppler ultrasonography. Urol Int 2005;75(1):75-79.
Ardicoglu A, Kocakoc E, Yuzgec V et al.
Hemodynamic effects of sildenafil citrate (Viagra) on
segmental branches of bilateral renal arteries.
International Urology & Nephrology 2005;37(4):785­
789.
Armstrong D K, Convery A G, Dinsmore W W.
Reasons for patient drop-out from an intracavernous
auto-injection programme for erectile dysfunction. Br
J Urol 1994;74(1):99-101.
D-99